Cancer Communications
indexed by SCI
BMC

Important notice

 

 

We would like to inform you that Chinese Journal of Cancer has changed the title to Cancer Communications on 1st March 2018.
Cancer Communications is published by Wiley from 1 January 2020. The journal website is available at: https://onlinelibrary.wiley.com/journal/25233548

 

 

Cancer Communications 最新影响因子突破5分

Cancer Communications (CJC) 获评“2019中国最具国际影响力学术期刊”


Long non‐coding RNA MILNR1 retards colorectal cancer growth by inhibiting c‐Myc
Hao Gu, Yang Xia, Lili Guo, Zifei Wang, Shuang Wu, Yuan Xu, Yaqin Zhang, Jing Huang Yu, Lei Wang,lai Hu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/22/2020   doi:10.1002/cac2.12079
T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications
Na Li, Jiani Yuan, Wenjia Tian, Lin Meng, Yongyu Liu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/17/2020   doi:10.1002/cac2.12074
Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
Qiuji Wu, Qian Chu, Hongyan Zhang, Bin Yang, Xudong He, Yahua Zhong, Xianglin Yuan, Melvin L.K. Chua, Conghua Xie
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/15/2020   doi:10.1002/cac2.12077
Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy
Shuning Ding, Xiaosong Chen, Kunwei Shen
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/12/2020   doi:10.1002/cac2.12078
Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
Zhihuan Lin, Yaxiong Zhang
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/8/2020   doi:10.1002/cac2.12070
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients
Zhong‐Guo, Zhou, Jin‐Bin Chen, Rong‐Xin Zhang, Ling Ye, Jun‐Cheng Wang, Yang‐Xun Pan, Xiao‐Hui Wang, Wen‐Xuan Li, Yao‐Jun Zhang, Li Xu, Min‐Shan Chen
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 7/1/2020   doi:10.1002/cac2.12069
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
Xiao‐Li Wei, Chao Ren, Feng‐Hua Wang, Yang Zhang, Hong‐Yun Zhao, Ben‐Yan Zou, Zhi‐Qiang Wang, Miao‐Zhen Qiu, Dong‐Sheng Zhang, Hui‐Yan Luo, Feng Wang, Sheng Yao, Rui‐Hua Xu
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 6/26/2020   doi:10.1002/cac2.12068
A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis
Jie Wu, Huibo Zhang, Lan Li, Mengxue Hu, Liang Chen, Bin Xu, Qibin Song
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 6/18/2020   doi:10.1002/cac2.12067
A safe and effective surgical navigation technique in laparoscopic radical gastrectomy: Indocyanine green‐mediated near‐infrared fluorescent imaging
Yan Qian, Shirong Cai
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 6/11/2020   doi:10.1002/cac2.12033
Modulating the Function of ABCB1: In Vitro and in Vivo Characterization of Sitravatinib, a Tyrosine Kinase Inhibitor
Yuqi Yang, Ning Ji, Chao-Yun Cai, Jing-Quan Wang, Zi-Ning Lei, Qiu-Xu Teng, Zhuo-Xun Wu, Qingbin Cui, Yihang Pan, Zhe-Sheng Chen
[ PDF Full-text ]    [ HTML Full-text ]     [ PubMed]   Epub: 6/11/2020   doi:10.1002/cac2.12040

more papers...






Gastric cancer  

 

Edited by Yun Dai and Li Yan
 

This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.

 

Read thematic series > 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Tumor angiogenesis  

 

Edited by Francesco Pezzella
and Chao-Nan Qian 

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.

 

Read thematic series > 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 

Lung cancer 


 

Edited by Lin Yan and Wei Zhang  

 

Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.

 

Read thematic series > 



CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East,Guangzhou 510060, P.R.China